



Cholangiocarcinoma  
Foundation®

## Research + Innovation: Funding for the Future

### 2026 SPONSORSHIP PROSPECTUS

CCF kindly requests that company pledges be submitted by **March 31, 2026**. If this date does not align with your company's policies or procedures, we are flexible and open to adjusting the deadline accordingly.

#### About the Cholangiocarcinoma Foundation

The Cholangiocarcinoma Foundation's (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). Founded in 2006 in Salt Lake City, Utah, by a family that lost a loved one to cholangiocarcinoma, CCF has become a leading global resource in patient support, education, advocacy, and funding basic, clinical, and translational research. The organization's core values are *patients first, collaboration, innovation, and urgency*.

#### About the CCF Research Program

The Research Program is dedicated to advancing scientific knowledge and fostering the development of the next generation of researchers through fellowship and grant opportunities, all aimed at improving patient outcomes. In 2015, CCF recognized the need to accelerate progress and launched the CCF Fellowship Program to assist early-career, innovative researchers globally studying cholangiocarcinoma. The program has since expanded to include support for mid- and senior-level researchers. Its goal is to help these CCA-focused researchers understand the disease's complexities and expedite the search for a cure. Supporting these projects can lead to advancements in understanding cholangiocarcinoma, developing new therapies, or improving healthcare practices.

Since 2006, we have funded over **\$6.4M** for CCA research. Our research is poised to change the trajectory of this disease, and your partnership will help accelerate this progress.

CCF chooses grant recipients carefully to ensure they build collaborations between researchers, institutions, and industry and share information, samples, and expertise with others in the field. Prior experience in the field of cholangiocarcinoma is not required.

CCF prioritizes funding for impactful projects related to cholangiocarcinoma that align with our research interests. To learn more about the program's research philosophy, [click here](#).

CCF offers two distinct award opportunities: a **1-Year Early-Career Research Fellowship** and a **3-Year Innovation Grant**. Together, these initiatives represent a commitment to research innovation and the cultivation of new scientific leaders. We select recipients to foster collaborations among researchers, institutions, and industry, facilitating sharing information, samples, and expertise within the field.

Recipients are notified at CCF's Annual Conference, and agreements begin in July. Funds include the costs of administering the award by CCF. In the event that all fellowships for the current funding cycle have been fully funded prior to receipt of a company's contribution, the funds will be automatically allocated to support fellowships in the subsequent funding cycle, unless the company submits a written request for the return of the contribution.

## CCF Fellowship Grant - 1 Year

This 1-year early-career CCF Research Fellowship offers an invaluable opportunity for emerging scientists to contribute to treating cholangiocarcinoma by generating new scientific insights that could transform patient care. Through this fellowship, researchers may explore innovative avenues for treatment, deepen our understanding of the disease's biology, and investigate why certain patients respond to treatments while others do not.

Over the years, it has become evident that achieving early funding significantly impacts the careers of many young investigators and leads to more funding, such as from federal granting agencies. Supporting a single early-career researcher can be a first step to creating a new laboratory, attracting additional CCF research funding, and developing novel CCA models that might not have been established otherwise.

CCF permits previous fellowship awardees to apply for supplemental funding for a second year, enabling them to become competitive for larger grants, such as the National Institutes of Health (NIH) or other ongoing funding sources. CCF aims to award 10 fellowships annually.

A grant of **\$85,000** allows us to award an early-career researcher the opportunity to undertake a research project that advances innovative approaches in the study of cholangiocarcinoma, fostering critical discoveries that could lead to improved treatments and patient outcomes.

## CCF Innovation Grant - 3 Years

The CCF Innovation Grant aims to fund and support senior-career researchers while integrating early- to mid-career researchers. This helps cultivate a skilled workforce and prepare the next generation of scientific leaders.

The CCF 3-Year Innovation Grants offer 3-year awards totaling **\$862,500 split over 3 years (\$287,500 per year)** and require collaboration between two or more institutions. We plan to expand by adding one new 3-year grant annually until we maintain a steady state of three Innovation Grants at any given time.

## Why Become a Sponsor

Sponsoring a research fellowship or grant allows your company to demonstrate its commitment to advancing medical research and improving patient outcomes in specific therapeutic areas of cholangiocarcinoma. This investment is an unrestricted grant and enhances your reputation as a leader in the industry, fosters collaborations with academic and clinical researchers, and provides early insights into innovative treatment developments.

Sponsorship Benefits

SPONSORSHIP BENEFITS	CCF Fellowship Grant 1 Year	CCF Innovation Grant 3 Years
	\$85,000	\$862,500 (\$287,500/Year x 3 Years)
Collaborative naming of a fellowship or grant	●	●
Recognition at the 2026 Annual Conference Awards Gala	●	●
Acknowledgment in the 2026 Annual Conference printed and digital program	●	●
Acknowledgment in communications, promotions, and social media coverage	●	●
Acknowledgment in any presentation and publication related to the award	●	●
Acknowledgement in CCF's Annual Report	●	●
Company recognition on the award-related CCF webpage	●	●
Potential to help retain early-career researchers in the field		●
Potential of translation to inform clinical practice		●
Support researchers that have committed their career tract within the CCA space		●
Greater likelihood of higher-impact publications		●
Support multi-institutional collaboration		●

SPONSORSHIP BENEFITS EXPLAINED

Collaborative naming of a fellowship or grant

Your company and CCF will jointly name the prestigious research fellowship or grant to advance critical cholangiocarcinoma research. By sponsoring the award, your company will demonstrate leadership in oncology, increase brand visibility, and have a lasting influence on patient care and scientific innovation. This partnership highlights your commitment to advancing life-saving research and supporting the cholangiocarcinoma community.

Recognition at the 2026 Annual Conference Awards Gala

Your company will receive special acknowledgment during the awards announcement at the 2026 Annual Conference, gaining visibility among top oncology professionals, researchers, and advocates.

Acknowledgment in the 2026 Annual Conference printed and digital program

Your company will be acknowledged in the 2026 Annual Conference program. Your company will gain valuable exposure with each conference attendee receiving a program.

Acknowledgment in communications, promotions, and social media coverage

Your company will be recognized in any communications, promotions, and social media coverage associated with the award. This includes emails, printed materials, digital representations, and social media posts. With **54,000+** social media followers, CCF offers significant exposure for your brand.

Acknowledgment in any presentation and publication related to the award

Your company will be recognized as a sponsor in any award-related presentation or publication.

## Acknowledgment in CCF's Annual Report

CCF's Annual Report reaches an estimated audience of **3,000** and is provided to all CCA stakeholders, including patients, caregivers, donors, and the public. Your company will be acknowledged as an award sponsor.

## Company recognition on the award-related CCF webpage

The collaborative naming of the award will be prominently featured on CCF's award-related webpage, which showcases current and past research awards. This page serves as a key resource for stakeholders and highlights the Foundation's commitment to advancing research in cholangiocarcinoma.

### 2025 Research Fellowship Awards in Partnership with Industry




#### AstraZeneca/CCF Research Fellowship

##### **Soravis Osataphan at Beth Israel Deaconess Medical Center**

*Mapping the tumor and immune microenvironment in liver-fluke-associated cholangiocarcinoma*

The AstraZeneca/CCF Research Fellowship grant, supported by AstraZeneca, focuses on the important role that scientific research plays in expanding knowledge about cholangiocarcinoma. This fellowship is awarded to Soravis Osataphan from Beth Israel Deaconess Medical Center. Soravis will investigate the mapping of the tumor and immune microenvironment in liver-fluke-associated cholangiocarcinoma.



#### Merck/CCF Research Fellowship

##### **Binbin Li at Mayo Clinic**

*Chemotherapy-Induced Senescence Promotes Tumor Immunosuppression in Cholangiocarcinoma*

The Merck/CCF Research Fellowship grant, supported by Merck & Co., focuses on the critical role of research in progressing treatment options for patients. This fellowship is awarded to Binbin Li from the Mayo Clinic. Binbin will investigate whether chemotherapy-induced senescence promotes tumor immunosuppression in cholangiocarcinoma.

### 2024 Research Fellowship Awards in Partnership with Industry




#### AstraZeneca/CCF Research Fellowship

##### **Pilar Acedo at Royal Free Hospital**

*Unraveling fibroinflammatory and immune signatures in PSC and CCA by spatial multiomics*

The AstraZeneca/CCF Research Fellowship grant, supported by AstraZeneca, focuses on the important role that scientific research plays in expanding knowledge about cholangiocarcinoma. This year's grant is awarded to Pilar Acedo from Royal Free Hospital, UCL, in the UK. Pilar will investigate unraveling fibroinflammatory and immune signatures in PSC and CCA by spatial multiomics.

### 2023 Research Fellowship Awards in Partnership with Industry



#### AstraZeneca/CCF Research Fellowship

##### **Martina Nebbia at Cedars-Sinai Medical Center**

*A safety switch for safe clinical application of tumor antigen-specific CAR -T cell immunotherapy in multi-focal and metastatic intrahepatic cholangiocarcinoma.*

The AstraZeneca/CCF Research Fellowship grant, supported by AstraZeneca, is being awarded to Martina Nebbia from Massachusetts General Hospital. Martina will be investigating a safety switch for safe clinical application of tumor antigen-specific CAR -T cell immunotherapy in multi-focal and metastatic intrahepatic cholangiocarcinoma.

CCF's obligation is fulfilled by delivering on the commitments articulated in this prospectus for the year indicated above, as well as by the value the sponsor receives from its association with CCF's intellectual capital, partners, and constituents.